GlassScriptPhysician profile
Ashley N Featherston
NPI 1144836347
$6,894.23
in general payments reported to CMS, 2019-2025
41 companies · $1,372 in 2025
The $1,372 reported for 2025 was more than what 92% of Clinical Nurse Specialist providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $612 · 2022: $1,425 · 2023: $1,762 · 2024: $1,723 · 2025: $1,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,857.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,856.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,702.65 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $915.24 | 2021-2025 | |
| Pfizer INC. | $556.50 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $310.37 | 2021-2025 | Ingrezza |
| Lilly USA, LLC | $243.54 | 2022-2025 | Zepbound, Emgality, Reyvow |
| Alexion Pharmaceuticals, INC. | $214.62 | 2022-2025 | Ultomiris |
| Springworks Therapeutics, INC. | $200.49 | 2024-2025 | Gomekli |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $181.16 | 2022-2023 | Trulance |
| Novo Nordisk INC | $179.29 | 2021-2022 | |
| Sk Life Science, INC. | $178.86 | 2022-2024 | Xcopri |
| Lundbeck LLC | $175.19 | 2021-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $138.47 | 2021-2024 | Ajovy, Austedo Xr |
| Emd Serono, INC. | $138.06 | 2022-2023 | Mavenclad |
| Amneal Pharmaceuticals LLC | $134.55 | 2022-2024 | Rytary, Crexont |
| Amgen INC. | $132.07 | 2024-2025 | Otezla, Uplizna |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $126.85 | 2024-2025 | Apokyn, Gocovri |
| Biogen, INC. | $108.30 | 2021-2025 | Vumerity |
| Astrazeneca Pharmaceuticals LP | $107.80 | 2021-2023 | Wainua |
| Corium, LLC | $97.04 | 2023 | Adlarity |
| Boston Scientific Corporation | $95.99 | 2022 | |
| Eisai INC. | $93.37 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $90.22 | 2025 | Stelara, Tremfya, Remicade |
| Sanofi-Aventis U.S. LLC | $89.94 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.17 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $79.77 | 2023 | Rexulti |
| Ucb, INC. | $76.73 | 2021-2024 | Briviact |
| Esperion Therapeutics, INC. | $73.77 | 2021 | |
| Neurelis, INC. | $62.72 | 2023-2025 | Valtoco |
| Alnylam Pharmaceuticals INC. | $50.45 | 2022-2023 | Onpattro |
| Argenx US, INC. | $40.54 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Genzyme Corporation | $36.55 | 2023 | |
| Acadia Pharmaceuticals INC | $23.53 | 2025 | Nuplazid |
| Kyowa Kirin, INC. | $21.27 | 2024 | Nourianz |
| Averitas Pharma INC. | $21.14 | 2023 | Qutenza |
| Horizon Therapeutics Plc | $19.76 | 2022 | |
| Banner Life Sciences, LLC | $19.61 | 2023 | |
| Genentech USA, INC. | $19.33 | 2024 | Ocrevus Zunovo |
| Biohaven Pharmaceutical Holding Company LTD. | $14.58 | 2022 | |
| Nevro Corp. | $13.52 | 2023 | Senza |
| Impel Pharmaceuticals INC. | $13.45 | 2023 | Trudhesa |
| Livanova USA, INC. | $12.77 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Featherston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.